Pharmed Ltd Annual Report | Financials | Balance Sheet for FY 2022-23

Pharmed Limited (Pharmed Limited) Return Comparision with Primex 40 Index

Periods	1 Week	1 Month	3 Months	6 Months	1 Year	3 Years	All Time
Primex-40
Pharmed Limited

PHARMED Limited Balance Sheet (In Rs. Crores)

Particulars	As at 31 March 2023	As at 31 March 2022
ASSETS
1) Non current assets
a)Property, Plant, and Equipment
i) Property, Plant, and Equipment	47.54	49.73
ii) Intangible Assets	0.10	0.12
iii) Capital work in progress	0.31	0.31
b) Goodwill on consolidation	29.11	29.11
c) Non current investments	141.06	113.72
c) Deferred Tax Assets (Net)	2.44	2.55
d) Other Non-Current Assets	0.58	0.49
Total non current assets	221.14	196.03
Current Assets
a) Inventories	31.02	32.24
b) Trade Receivables	18.83	17.26
c) Cash and Cash Equivalents	12.73	4.42
d) Short Term Loans and Advances	6.06	12.26
Total current assets	68.64	66.18
Total Assets	289.78	262.21
EQUITY AND LIABILITIES
EQUITY
a) Equity Share capital	0.86	0.86
b) Other equity	230.19	198.74
Total Equity	231.05	199.60
LIABILITIES
Non-current Liabilities
a) Other Long Term liabilities	4.26	2.83
b) Long Trem Provisions	4.99	4.53
Total non current liabilities	9.25	7.36
Current liabilities
a)Trade payables
Total outstanding dues of micro and small Enterprises	20.24	24.06
Total outstanding dues of creditors other than micro and small enterprises	3.71	12.56
b) Other current liabilities	4.27	5.81
c) Short Term Provisions	21.26	12.82
Total current liailities	49.48	55.25
Total liabilities	58.73	62.61
Total Equity and liabilities	289.78	262.21

PHARMED Limited Profit & Loss Statement (In Rs. Crores)

PARTICULARS	2023	2022
Revenue from Operations	425.99	350.19
Other Income	9.98	9.45
Total Revenue	435.97	359.64
Expenses
Purchase of Stock in Trade	127.66	100.37
Changes In Inventories of Stock in Trade	1.22	-6.25
Employee Benefits Expense	129.97	97.79
Finance Cost	0.36	0.30
Other Expenses	130.39	110.09
Depreciation and Amortisation Expense	3.27	2.32
Total Expenses	392.87	304.62
Profit before Tax	43.10	55.02
Tax Expense
1) Current Tax	10.03	13.08
2) Deferred Tax	0.10	-0.39
Profit for the year	32.97	42.33
Earnings per Equity share (Face Value Per Share)
a) Basic (Rs.)	76.54	98.27
b) Diluted (Rs.)	76.54	98.27

PHARMED Limited’s Cash Flow Statement (In Rs. Crores)

Particulars	31st March 2023	31 March 2022
A. Cash Flow from Operating Activities
Profit/(Loss) Before Tax	43.10	55.02
Adjustments for:
Depreciation and amortisation expenses	3.27	2.32
Finance cost	0.36	0.30
Interest Income	-0.81	-0.70
Net(gain) / Loss on sale of Investments	-8.62	-7.83
Rental Income from Investment Properties	-0.04	-0.04
(Gain) / Loss on sale of Asset	0.01	0.01
Cash generated from operations before working capital changes	37.27	49.08
Working capital changes
Adjustments for (increase)/decrease in operating Assets
Inventories	1.22	-6.25
Trade receivables	-1.57	-0.93
Short term loan and advances	5.06	-5.23
Long term Loans and advances	-	1.20
Other non current assets	-0.09	-0.16
Adjustments for (increase)/decrease in operating liabilities
Trade payables	-12.66	12.56
Other current liabilities	-1.54	2.73
Other Long term liabilities	1.43	0.30
Long term provisions	0.44	0.64
Short Term provisions	8.44	-0.07
Operating profit after working capital changes	38.00	53.87
Income tax paid, net of refunds	-8.99	-14.12
Net cash generated from operating activities	29.01	39.75
Cash flows from investing activities
Capital Expenditure on Fixed Assets, including capital advances	-1.13	-41.97
Proceeds from sale of property, plant & equipment	0.06	0.55
Purchase of long term investments	-104.55	-49.48
Proceeds from sale of long term investments	85.83	52.13
Interest Received	0.81	0.70
Rental Income Received	0.04	0.04
Net cash used in investing activities	-18.94	-38.03
Cash flows from financing activities
Dividend paid	-0.36	-0.30
Finance cost	-1.51	-3.01
Tax on Dividend
Net cash used in financing activities	-1.87	-3.31
Net increase/ (decrease) in cash and cash equivalent	8.20	-1.59
Add: Cash and Cash Equivalent at beginning of year	4.35	5.94
Cash and cash equivalents as at end of year	12.55	4.35
Cash and Cash Equivalent comprise the following
Cash on hand	0.08	0.16
Balance with bank
In Current Account	12.65	4.27
Total	12.73	4.43

PHARMED Limited Key Financial Ratios ( Standalone)

Particulars	31-Mar-23	31-Mar-22
Current Ratio (in times)	1.4	1.21
Debt-Equity Ratio (in times)	0	0
Debt Service Coverage Ratio (in times)	0	0
Return on Equity Ratio (in %)	14.44%	21.41%
Inventory Turnover Ratio (in times)	13.47	12.03
Trade Receivables Turnover Ratio (in times)	23.61	20.85
Trade Payable Turnover Ratio (in times)	4.22	3.31
Net Capital Turnover Ratio (in times)	27.45	26.89
Net Profit Ratio (in %)	7.77%	12.08%
Return on investment	6.74%	7.57%
Return on Capital Employed Ratio (in %)	19.00%	28.00%

PHARMED Limited share Dividend History

Particulars	2023	2022
Dividend per Share	3.5	3.5
Retained Earnings (In Rs. Crores)	228.4	196.81

PHARMED Limited Recent Financial Performance for FY 2023

Revenue from Operations: Revenue increased by ₹75.80 crores from 2022 to 2023, indicating potential growth in the core business.

Other Income: Other income remained relatively stable, with a slight increase from ₹9.45 crores in 2022 to ₹9.98 crores in 2023.

Total Revenue: Total revenue increased by ₹76.33 crores from 2022 to 2023, reflecting both core business growth and stable other income.

Total Expenses: Total expenses increased from ₹304.62 crores in 2022 to ₹392.87 crores in 2023, possibly due to increased costs.

Profit before Tax: Profit before tax decreased by ₹11.92 crores from 2022 to 2023, indicating lower pre-tax profitability in 2023.

Profit for the Year: The profit for the year decreased by ₹9.36 crores from 2022 to 2023.

Earning per Equity Share - Basic and Diluted: Basic and diluted earnings per equity share decreased significantly from ₹98.27 in 2022 to ₹76.54 in 2023, indicating reduced earnings per share.

Pharmed Ltd Annual Report & Financials